These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35790169)

  • 1. [Successful local treatment of a digital canine mast cell tumour with Tigilanol Tiglate].
    Gasser K
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2022 Jun; 50(3):225-231. PubMed ID: 35790169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate.
    Brown GK; Campbell JE; Jones PD; De Ridder TR; Reddell P; Johannes CM
    Front Vet Sci; 2021; 8():675804. PubMed ID: 34513966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
    De Ridder TR; Campbell JE; Burke-Schwarz C; Clegg D; Elliot EL; Geller S; Kozak W; Pittenger ST; Pruitt JB; Riehl J; White J; Wiest ML; Johannes CM; Morton J; Jones PD; Schmidt PF; Gordon V; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):415-429. PubMed ID: 32542733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate.
    Reddell P; De Ridder TR; Morton JM; Jones PD; Campbell JE; Brown G; Johannes CM; Schmidt PF; Gordon V
    J Vet Intern Med; 2021 Jan; 35(1):430-441. PubMed ID: 33438258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.
    Jones PD; Campbell JE; Brown G; Johannes CM; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):451-455. PubMed ID: 33350511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.
    De Ridder T; Reddell P; Jones P; Brown G; Campbell J
    Front Vet Sci; 2021; 8():764800. PubMed ID: 34977208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.
    Brown GK; Finlay JR; Straw RC; Ziea JY; Leung B; O'Connell K; Thomson MJ; Campbell JE; Jones PD; Reddell P
    Front Vet Sci; 2022; 9():1003165. PubMed ID: 36387404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.
    Miller J; Campbell J; Blum A; Reddell P; Gordon V; Schmidt P; Lowden S
    Front Vet Sci; 2019; 6():106. PubMed ID: 31111038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses.
    De Ridder T; Ruppin M; Wheeless M; Williams S; Reddell P
    Front Vet Sci; 2020; 7():639. PubMed ID: 33033726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast cell tumour and cutaneous histiocytoma excision wound healing in general practice.
    Killick DR; Rowlands AM; Burrow RD; Cripps P; Miller J; Graham P; Blackwood L
    J Small Anim Pract; 2011 Sep; 52(9):469-75. PubMed ID: 21896021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome.
    Saunders H; Thomson MJ; O'Connell K; Bridges JP; Chau L
    Vet Comp Oncol; 2021 Dec; 19(4):604-615. PubMed ID: 32558125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery.
    Baker-Gabb M; Hunt GB; France MP
    Aust Vet J; 2003 Dec; 81(12):732-8. PubMed ID: 15080482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presumptive primary intrathoracic mast cell tumours in two dogs.
    Cartagena-Albertus JC; Moise A; Moya-García S; Cámara-Fernández N; Montoya-Alonso JA
    BMC Vet Res; 2019 Jun; 15(1):204. PubMed ID: 31208404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
    Kiupel M; Webster JD; Miller RA; Kaneene JB
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic mast cell tumour in a dog presenting with spinal pain.
    Cooper MA; Bennett PF; Laverty PH
    Aust Vet J; 2009 Apr; 87(4):157-9. PubMed ID: 19335472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision.
    Weisse C; Shofer FS; Sorenmo K
    J Am Anim Hosp Assoc; 2002; 38(1):71-3. PubMed ID: 11804319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs.
    Selmic LE; Ruple A
    BMC Vet Res; 2020 Jan; 16(1):5. PubMed ID: 31906934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumours.
    Marconato L; Polton G; Stefanello D; Morello E; Ferrari R; Henriques J; Tortorella G; Benali SL; Bergottini R; Vasconi ME; Annoni M; Sabattini S
    Vet Comp Oncol; 2018 Dec; 16(4):580-589. PubMed ID: 30047226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
    Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
    J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours.
    Donnelly L; Mullin C; Balko J; Goldschmidt M; Krick E; Hume C; Brown DC; Sorenmo K
    Vet Comp Oncol; 2015 Mar; 13(1):70-6. PubMed ID: 23451809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.